Comment on “A smaller proportion of circulating biologically active parathyroid hormone in peritoneal dialysis does not allow inter-method adjustment of established parathyroid hormone for haemodialysis”

Nefrologia 2015;35(1):117

To the Editor,
We have read with much interest the article by M. Luisa González-Casaus et al. on the difficulty of performing an inter-method adjustment of parathyroid hormone (PTH) measurement in peritoneal dialysis patients due to significant differences in the quantity of biologically active PTH present in patients who receive peritoneal dialysis compared with those who receive haemodialysis. There is increasing criticism of using intact PTH as a biomarker for the monitoring and follow-up of bone turnover in patients on dialysis and a need to find new and more efficient markers.

The observation of the authors regarding serum BCTx (beta crosslaps) is very interesting. Table 5 of this article clearly demonstrates how, while no intact PTH assay shows significant differences between haemodialysis and peritoneal dialysis patients, these bone turnover markers do show very significant differences.

Serum BCTx are fragments that form as a result of the degradation of type I collagen that are released during osteoclastic bone resorption. BCTx are used assiduously in the monitoring of the therapeutic effectiveness of treatment with bisphosphonates and other antiresorptive drugs in the treatment of postmenopausal osteoporosis and they are capable of predicting hip fracture independently of bone densitometry. These markers have a low intra-assay coefficient of variation when they are measured by ElecsyR in automatic analysers. In addition, they have a good correlation with other bone markers in patients on haemodialysis and those on peritoneal dialysis.

In conclusion, we believe that serum BCTx are promising markers in the evaluation of bone turnover in dialysis patients and should be included in prospective longitudinal studies to analyse their capacity in predicting bone turnover assessed by bone histomorphometry.

Conflicts of interest
The author declares that he has no conflicts of interest related to the contents of this article.


Armando Luis Negri
Servicio de Nefrología.
Instituto de Investigaciones Metabólicas.
Universidad del Salvador. Buenos Aires, CABA (Argentina).

Comment on «Management of hypercalcemia after renal transplantation»

Nefrologia 2015;35(1):117-8

Dear Editor,
We read with great interest the short reviews by José V. Torregrosa et Xoana Barros, where the authors discussed the problem of withdrawal the calcimimetic at the time of renal transplantation (RT) which seems to be of high predictive importance in a higher prevalence of hypercalcemia and hyperparathyroidism in these patients. The authors also propose a very practical and clear algorithm for managing hypercalcemia after RT.

Cinacalcet is the only available calcimimetic agent. It was approved for the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients and parathyroid carcinoma. However, cinacalcet isn’t approved for RT recipients and has to be withheld at the time of transplantation.

A rebound hyperparathyroidism (HPT) may be hypothesized to occur, which may increase the risk for persistent HPT and related morbidity.

Surprisingly, the literature on evaluating the effects of discontinuing cinacalcet at the time of RT is very scanty and limited by low patients numbers, retrospective design and data concerning clinical outcomes.

Correspondence: Armando Luis Negri
Servicio de Nefrología.
Instituto de Investigaciones Metabólicas.
Universidad del Salvador, Libertad 836 1 piso, 1012, Buenos Aires, CABA, Argentina. negri@casasco.com.ar armando.negri@gmail.com